Document registry — page 36
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Observational, phase 2 study of Kisspeptin-10 in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low21 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in sleep apnoea and obesity randomising 359 participants over 32 weeks. Primary result…
Moderate20 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing randomising 30 participants over 12 weeks. Primary result: No significant…
Low19 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low19 Sep 2023 -
Record of documents ratified in the 2023 Q3 assessment cycle.
18 Sep 2023 -
Single-arm open-label, phase 1 study of GHRP-6 in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this record…
Very low18 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low18 Sep 2023 -
Single-arm open-label, phase 3 study of Thymosin alpha-1 in immune modulation over open-label extension of the parent trial. The Institute holds no reported primary…
Very low18 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Sep 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Sep 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low16 Sep 2023 -
Randomised crossover, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low16 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy randomising 412 participants over 26 weeks. Primary result: Mean change −15.2…
Moderate15 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low15 Sep 2023 -
Single-arm open-label, phase 3 study of Dulaglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low15 Sep 2023 -
Observational, phase 3 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low15 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low15 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity and prediabetes randomising 304 participants over 104 weeks. Primary result: Mean…
High13 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in type 2 diabetes randomising 383 participants over 26 weeks. Primary result: Reduction of…
Moderate12 Sep 2023 -
Single-arm open-label, phase 2 study of Thymosin beta-4 in wound healing over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low12 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low12 Sep 2023 -
Observational, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low12 Sep 2023 -
Single-arm open-label, phase 3 study of Teduglutide in mucosal barrier randomising 88 participants over 24 months. Primary result: Reductions were maintained during…
Moderate11 Sep 2023 -
Single-arm open-label, phase 3 study of Liraglutide in prediabetes and obesity over open-label extension of the parent trial. The Institute holds no reported primary…
Very low11 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low11 Sep 2023 -
Single-arm open-label, phase 3 study of Semaglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low11 Sep 2023 -
Phase 1 ascending dose, phase 1 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Sep 2023 -
Single-arm open-label, phase 3 study of Pramlintide in type 1 diabetes (adjunct) over open-label extension of the parent trial. The Institute holds no reported primary…
Very low11 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low10 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy randomising 404 participants over 26 weeks. Primary result: Directionally…
Moderate08 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in type 2 diabetes randomising 411 participants over 16 weeks. Primary result: Glycaemic…
07 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low07 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low07 Sep 2023 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in hfpef over as stated in the parent protocol. The Institute holds no reported…
Very low05 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Sep 2023 -
Randomised crossover, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low05 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Sep 2023
page 36 of 41